Transcode Therapeutics Inc (RNAZ) - Total Assets
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) holds total assets worth $162.40 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Transcode Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Transcode Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Transcode Therapeutics Inc (RNAZ) shareholders funds for net asset value and shareholders' equity analysis.
Transcode Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Transcode Therapeutics Inc's total assets of $162.40 Million consist of 13.5% current assets and 86.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $3.25 Million | 2.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $114.30 Million | 70.4% |
| Goodwill | $25.74 Million | 15.9% |
Asset Composition Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RNAZ stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Transcode Therapeutics Inc's current assets represent 13.5% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 99.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 85.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 70.4% of total assets.
Transcode Therapeutics Inc Competitors by Total Assets
Key competitors of Transcode Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Transcode Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.29 | 5.20 | 0.35 |
| Quick Ratio | 6.29 | 5.20 | 0.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $18.49 Million | $10.53 Million | $-992.88K |
Transcode Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Transcode Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 2126.3% |
| Total Assets | $162.40 Million |
| Market Capitalization | $4.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Transcode Therapeutics Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Transcode Therapeutics Inc's assets grew by 2126.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Transcode Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $162.40 Million | +2126.32% |
| 2024-12-31 | $7.29 Million | +41.10% |
| 2023-12-31 | $5.17 Million | -31.87% |
| 2022-12-31 | $7.59 Million | -66.92% |
| 2021-12-31 | $22.94 Million | +2073.50% |
| 2020-12-31 | $1.06 Million | +386.92% |
| 2019-12-31 | $216.74K | +0.98% |
| 2018-12-31 | $214.65K | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more